Montara Therapeutics, a San Francisco, CA-based biotech firm empowering brain-selective therapies for CNS illnesses, raised $20M in Seed funding.
Backers included SV Well being Traders’ Dementia Discovery Fund, Two Bear Capital, Dolby Household Ventures, and KdT Ventures, together with new investments from BEVC and extra buyers, bringing the full quantity to $28M. In reference to the financing, Troy E. Wilson, Ph.D., J.D., has joined Montara as an Impartial Director and Chairman of the Board. Dr. Wilson, a serial entrepreneur and present President and CEO of Kura Oncology, has based and operated a number of firms, together with Kura, Avidity Biosciences, Wellspring Biosciences, Araxes Pharma, Intellikine, and Ambrx. Dr. Wilson can also be collaborating within the Seed spherical as an investor.
The corporate intends to sue the funds to broaden operations and its R&D efforts.
Led by Nicholas T. Hertz, Ph.D., Founder and CEO, Montara is a preclinical-stage biopharmaceutical firm pursuing novel approaches to develop safer and extra efficacious therapies for neurological illnesses. Its BrainOnly™ platform is designed to enhance the therapeutic index of CNS medicine and allow larger, simpler dosing of CNS-targeted therapies by blocking peripheral unwanted side effects, addressing main security and tolerability challenges within the therapy of varied neurological illnesses.
FinSMEs
13/03/2025
